173 related articles for article (PubMed ID: 25260803)
1. High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.
Zhang K; Chen H; Wu G; Chen K; Yang H
Med Oncol; 2014 Nov; 31(11):247. PubMed ID: 25260803
[TBL] [Abstract][Full Text] [Related]
2. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.
Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H
Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
[TBL] [Abstract][Full Text] [Related]
4. High expression of survivin in sacral chordoma.
Chen C; Yang HL; Chen KW; Wang GL; Lu J; Yuan Q; Gu YP; Luo ZP
Med Oncol; 2013 Jun; 30(2):529. PubMed ID: 23504337
[TBL] [Abstract][Full Text] [Related]
5. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
[TBL] [Abstract][Full Text] [Related]
6. PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
Li Z; Lv T; Liu Y; Huang X; Qiu Z; Li J
Cancer Biomark; 2016 Mar; 16(4):633-9. PubMed ID: 27002766
[TBL] [Abstract][Full Text] [Related]
7. Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma.
Zhou M; Chen K; Yang H; Wang G; Lu J; Ji Y; Wu C; Chen C
J Neurooncol; 2014 Jan; 116(1):77-82. PubMed ID: 24135846
[TBL] [Abstract][Full Text] [Related]
8. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
[TBL] [Abstract][Full Text] [Related]
9. Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis.
Chen H; Zhang K; Wu G; Song D; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(11):14741-8. PubMed ID: 26823799
[TBL] [Abstract][Full Text] [Related]
10. ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma.
Ding Y; Bui MM; Wang Q; Sun X; Zhang M; Niu X; Tian W
Ann Clin Lab Sci; 2019 May; 49(3):309-316. PubMed ID: 31308029
[TBL] [Abstract][Full Text] [Related]
11. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
[TBL] [Abstract][Full Text] [Related]
12. Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution.
van Wulfften Palthe ODR; Tromp I; Ferreira A; Fiore A; Bramer JAM; van Dijk NC; DeLaney TF; Schwab JH; Hornicek FJ
Spine J; 2019 May; 19(5):869-879. PubMed ID: 30445184
[TBL] [Abstract][Full Text] [Related]
13. What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?
Ji T; Guo W; Yang R; Tang X; Wang Y; Huang L
Clin Orthop Relat Res; 2017 Mar; 475(3):620-630. PubMed ID: 26975382
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.
Hobusch GM; Bodner F; Walzer S; Marculescu R; Funovics PT; Sulzbacher I; Windhager R; Panotopoulos J
World J Surg Oncol; 2016 Apr; 14():111. PubMed ID: 27091202
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients.
Zou MX; Huang W; Wang XB; Li J; Lv GH; Wang B; Deng YW
Eur Spine J; 2015 Aug; 24(8):1738-46. PubMed ID: 25850393
[TBL] [Abstract][Full Text] [Related]
16. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.
Yang Y; Niu X; Li Y; Liu W; Xu H
Eur Spine J; 2017 Jul; 26(7):1910-1916. PubMed ID: 27942938
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence.
Li X; Wang S; Chen Y; Liu G; Yang X
Onkologie; 2013; 36(10):567-71. PubMed ID: 24107910
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma.
He G; Liu X; Pan X; Ma Y; Liu X
Clin Transl Oncol; 2020 Dec; 22(12):2324-2332. PubMed ID: 32504188
[TBL] [Abstract][Full Text] [Related]
19. Role of intraoperative radiotherapy in the treatment of sacral chordoma.
Jullien-Petrelli AC; García-Sabrido JL; Orue-Echebarria MI; Lozano P; Álvarez A; Serrano J; Calvo FM; Calvo-Haro JA; Lasso JM; Asencio JM
Spine J; 2018 Apr; 18(4):632-638. PubMed ID: 28882523
[TBL] [Abstract][Full Text] [Related]
20. Low expression of miRNA-1290 associated with local invasion and recurrence in sacral chordoma.
Wang Y; Chen K; Chen H; Zhang K; Lu J; Mao H; Yang H
Int J Clin Exp Pathol; 2017; 10(11):10934-10940. PubMed ID: 31966437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
